Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer

Trial Profile

A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary) ; Bicalutamide; Goserelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2022 This trial has been completed in Spain, according to European Clinical Trial database record.
    • 15 Apr 2014 Results from a pooled analysis presented at the 29th Congress of the European Association of Urology.
    • 13 Feb 2013 German Clinical Trials Register reports actual trial initiation date as 30 Apr 2009.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top